医药行业周专题：减重需求正盛，多方向酝酿破局

Investment Rating - The report maintains a "Positive" outlook on the pharmaceutical and biotechnology industry, particularly focusing on the weight loss market driven by GLP-1RAs [9]. Core Insights - The global weight loss market is rapidly expanding, with significant growth in GLP-1RAs, which saw sales reach $15.96 billion in Q1 2025, a year-on-year increase of 47.9% [9][15]. - The development trend is shifting from merely achieving weight loss to enhancing the quality of weight loss, with a focus on long-acting formulations, oral medications, and multi-target molecules [9][22]. - Major multinational corporations (MNCs) are actively positioning themselves in the weight loss sector, creating numerous business development opportunities [9][30]. Summary by Sections 1. Weight Loss Market Surge - The GLP-1RAs market is experiencing high growth, with Q1 2025 sales reaching $15.96 billion, a 47.9% increase year-on-year [9][15]. - Semaglutide has become the new "king of drugs" with sales of $8.38 billion, surpassing other major drugs [9][19]. 2. Development Trends: From Quantity to Quality - Current weight loss drugs are achieving results comparable to surgical interventions, with average weight loss figures nearing those of surgical procedures [22]. - The focus is on long-acting, oral formulations, and multi-target combinations to improve patient adherence and reduce lean body mass loss [22][23]. 2.1 Long-Acting Formulations - ASC30 has the longest half-life among long-acting formulations, supporting potential monthly dosing [23][25]. - MariTide and GZR18 are the fastest progressing long-acting formulations in clinical trials [23][27]. 2.2 Oral Formulations - Oral formulations are being developed primarily in peptide and small molecule categories, with semaglutide tablets nearing NDA submission [30][31]. - Orforglipron is expected to submit NDA by the end of 2025, potentially becoming the first approved oral GLP-1RA [46]. 2.3 Multi-Target Molecules - Multi-target molecules like GLP-1R/GIPR are gaining traction, with several in clinical development [50]. - The report highlights the potential of new targets and combinations to enhance weight loss efficacy [50]. 3. MNCs Actively Positioning - MNCs are increasingly engaging in significant transactions within the weight loss sector, with Eli Lilly and Novo Nordisk leading the way [9][30]. - There are substantial business development opportunities for domestic companies in the weight loss market due to their competitive advantages [9][30].